The combination of atezolizumab (an anti-PD-L1antibody) and bevacizumab (an anti-VEGF antibody) became a new standard of care in the first-line setting for advanced HCC based on an unprecedented overall (OS) benefit [8]. Here, VEGFA is linked to hepatocellular carcinoma.